The NASDAQ 100 Pre-Market Indicator is up 48.15 to 21,488.97. The total Pre-Market volume is currently 146,502,773 shares traded.
The following are the most active stocks for the pre-market session:
Cumberland Pharmaceuticals Inc. (CPIX) is +1.91 at $3.15, with 48,308,434 shares traded.
Chimerix, Inc. (CMRX) is +1.415 at $2.28, with 19,388,924 shares traded. As reported by Zacks, the current mean recommendation for CMRX is in the "strong buy range".
uniQure N.V. (QURE) is +7.5947 at $14.89, with 10,324,120 shares traded. As reported by Zacks, the current mean recommendation for QURE is in the "buy range".
NIO Inc. (NIO) is -0.23 at $4.95, with 6,711,299 shares traded. NIO's current last sale is 82.5% of the target price of $6.
NVIDIA Corporation (NVDA) is +0.06 at $138.87, with 4,172,976 shares traded. Over the last four weeks they have had 11 up revisions for the earnings forecast, for the fiscal quarter ending Jan 2025. The consensus EPS forecast is $0.79. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
C3.ai, Inc. (AI) is -2.89 at $38.79, with 3,504,843 shares traded., following a 52-week high recorded in prior regular session.
Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.36 at $27.44, with 3,267,790 shares traded., following a 52-week high recorded in prior regular session.
Lucid Group, Inc. (LCID) is +0.011 at $2.56, with 3,152,444 shares traded. LCID's current last sale is 85.37% of the target price of $3.
BigBear.ai, Inc. (BBAI) is -0.1601 at $3.50, with 2,722,473 shares traded. As reported by Zacks, the current mean recommendation for BBAI is in the "buy range".
D-Wave Quantum Inc. (QBTS) is +0.08 at $4.73, with 2,047,189 shares traded. As reported by Zacks, the current mean recommendation for QBTS is in the "buy range".
IonQ, Inc. (IONQ) is -1.12 at $33.12, with 1,545,494 shares traded. IONQ's current last sale is 184% of the target price of $18.
Oracle Corporation (ORCL) is -12.3058 at $178.14, with 739,049 shares traded. As reported by Zacks, the current mean recommendation for ORCL is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
